HilleVax Inc (HLVX) News

HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is...

Form 8-K - Current report

HilleVax Announces Reduction in Force

BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical...

Form 8-K - Current report

BP Slashes Profit Forecast by $700 Million; Morgan Stanley Predicts S&P 500 10% Drop, and More News

BP plc (NYSE:BP) – BP expects weak margins in its refining business to impact its second-quarter profits...

Form 8-K - Current report

HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants

The NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will...

Form 8-K - Current report

Form EFFECT - Notice of Effectiveness

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million...

HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress

Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 Enrollment for...

Form 4 - Statement of changes in beneficial ownership of securities